Related Experiment Video
Updated: Sep 14, 2025

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
Effects of erythromycin dosage on clinical outcomes in stable non-cystic fibrosis bronchiectasis: A randomized
Junguo Zhang1, Yunpeng Chen1, Peng Zhang1
1Pulmonology Department, Fengdu General Hospital, Chongqing, China.
Background:
This study evaluates the efficacy and side effects of different doses of erythromycin in patients with stable non-cystic fibrosis bronchiectasis (NCFB).
Methods:
Altogether, 148 patients diagnosed with stable NCFB were enrolled in this study and randomly assigned to one of the following 4 treatment groups: Group A received erythromycin 250 mg/d; Group B received erythromycin 375 mg/d; Group C received erythromycin 500 mg/d; and Group D received a placebo. Each group consisted of 35 patients. The dataset comprised lung function data and computed tomography, St. George respiratory questionnaire, modified Medical Research Council, bronchiectasis severity index (BSI), and exacerbations, FEV1, age, chronic colonization, extension, dyspnea scores, which were collected before and at 6 months after treatment. These were subjected to a univariate analysis.
Results:
Groups C and D exhibited significant differences in forced expiratory volume in 1 second, forced vital capacity, quality of life, and computed tomography Bhalla, BSI, and E-FACED scores (P < .05). Additionally, Groups B and D demonstrated significant differences in forced vital capacity and St. George respiratory questionnaire, BSI, and E-FACED scores (P < .05). Contrarily, Group A exhibited nonsignificant differences.
Conclusion:
The oral erythromycin regimen at a dose of 500 mg/d can improve the lung function and quality of life of stable NCFB patients.
Related Concept Videos
Cystic Fibrosis: Management
Sinus disease and chronic...
COPD: Management Using Bronchodilators and Corticosteroids
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

